Search Results for "manifestation"
Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.
More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.
For more information about our FDA-approved therapies, please see the Full Prescribing Information:
Diagnosing AHP Infographic
This infographic discusses the clinical and demographic presentation of an AHP patient and how to assess for AHP diagnosis.
This infographic discusses the clinical and demographic presentation of an AHP patient and how to assess for AHP diagnosis.
Understanding ATTR Amyloidosis
Understanding ATTR amlyloidosis: This slide deck highlights an overview of ATTR amyloidosis pathophysiology, symptom onset and prevalence
Understanding ATTR amlyloidosis: This slide deck highlights an overview of ATTR amyloidosis pathophysiology, symptom onset and prevalence
ATTR-CM HELIOS-B Data Summary
ATTR-CM HELIOS-B Data Summary deck provides a comprehensive overview of the HELIOS-B results. Also includes information on ATTR-CM and the MOA of RNAi therapeutics.
ATTR-CM HELIOS-B Data Summary deck provides a comprehensive overview of the HELIOS-B results. Also includes information on ATTR-CM and the MOA of RNAi therapeutics.
Phase 3 HELIOS-B Study Rationale
This slide deck highlights the Phase 3 trial design for HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy.
This slide deck highlights the Phase 3 trial design for HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy.
ATTR Disease Management
This deck highlights management and monitoring of patients with ATTR.
This deck highlights management and monitoring of patients with ATTR.
RNAi Data Navigator: Focus on Vutrisiran
This interactive PDF provides an overview of ATTR-CM and RNAi therapeutics, and offers a deep dive into the vutrisiran data in ATTR-CM from the HELIOS-B trial, including the primary and additional analyses. Alnylam's ongoing commitment to ATTR amyloidosis is reflected in a summary of the current pipeline and TRITON-CM study design.
This interactive PDF provides an overview of ATTR-CM and RNAi therapeutics, and offers a deep dive into the vutrisiran data in ATTR-CM from the HELIOS-B trial, including the primary and additional analyses. Alnylam's ongoing commitment to ATTR amyloidosis is reflected in a summary of the current pipeline and TRITON-CM study design.
Patisiran: Patients with Heart Transplant
Standard response letter on patisiran and use in patients with heart transplant.
Standard response letter on patisiran and use in patients with heart transplant.
Patisiran: Pregnancy and Lactation
Standard response letter on patisiran and pregnancy & lactation. This letter contains information on preclinical toxicology studies and the APOLLO, APOLLO-B, and HELIOS-A studies.
Standard response letter on patisiran and pregnancy & lactation. This letter contains information on preclinical toxicology studies and the APOLLO, APOLLO-B, and HELIOS-A studies.
Diagnosing PH1 Infographic
This infographic discusses the clinical and demographic presentation of a PH1 patient and how to assess for PH1 diagnosis
This infographic discusses the clinical and demographic presentation of a PH1 patient and how to assess for PH1 diagnosis
Insights from the HELIOS-A Study
This deck highlights data from the Phase 3 HELIOS-A trial of vutrisiran in patients with hATTR-PN.
This deck highlights data from the Phase 3 HELIOS-A trial of vutrisiran in patients with hATTR-PN.
Lumasiran Clinical Program Overview
This infographic details the lumasiran clinical program (including ILLUMINATE) which investigates the treatment of primary hyperoxaluria type 1 with lumasiran.
This infographic details the lumasiran clinical program (including ILLUMINATE) which investigates the treatment of primary hyperoxaluria type 1 with lumasiran.
